CL2022000089A1 - Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida. - Google Patents

Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.

Info

Publication number
CL2022000089A1
CL2022000089A1 CL2022000089A CL2022000089A CL2022000089A1 CL 2022000089 A1 CL2022000089 A1 CL 2022000089A1 CL 2022000089 A CL2022000089 A CL 2022000089A CL 2022000089 A CL2022000089 A CL 2022000089A CL 2022000089 A1 CL2022000089 A1 CL 2022000089A1
Authority
CL
Chile
Prior art keywords
inden
polymorphs
carboxamide
dihydro
isopropyl
Prior art date
Application number
CL2022000089A
Other languages
English (en)
Spanish (es)
Inventor
Norma TOM
Denise Andersen
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CL2022000089A1 publication Critical patent/CL2022000089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2022000089A 2019-07-17 2022-01-12 Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida. CL2022000089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17

Publications (1)

Publication Number Publication Date
CL2022000089A1 true CL2022000089A1 (es) 2022-10-07

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000089A CL2022000089A1 (es) 2019-07-17 2022-01-12 Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il) -2-metil-2h- tetrazole-5-carboxamida.

Country Status (16)

Country Link
US (1) US12649732B2 (cg-RX-API-DMAC10.html)
EP (1) EP3999181B1 (cg-RX-API-DMAC10.html)
JP (1) JP2022542803A (cg-RX-API-DMAC10.html)
KR (1) KR20220082803A (cg-RX-API-DMAC10.html)
CN (1) CN114667283B (cg-RX-API-DMAC10.html)
AU (1) AU2020315433A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022000523A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144974A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000089A1 (cg-RX-API-DMAC10.html)
ES (1) ES2982707T3 (cg-RX-API-DMAC10.html)
IL (1) IL289881A (cg-RX-API-DMAC10.html)
MX (1) MX2022000498A (cg-RX-API-DMAC10.html)
NZ (1) NZ784931A (cg-RX-API-DMAC10.html)
PH (1) PH12022550084A1 (cg-RX-API-DMAC10.html)
TW (1) TW202116764A (cg-RX-API-DMAC10.html)
WO (1) WO2021011809A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399866B2 (en) * 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006284751A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
MX2012000437A (es) 2009-07-08 2012-02-21 Chelsea Therapeutics Inc Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico.
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
EP3151671A4 (en) 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
DK3356345T3 (da) 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
EP3156049A1 (en) 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmaceutical composition of prasugrel
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
WO2024182469A1 (en) 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
CN120712262A (zh) 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025220034A1 (en) 2024-04-16 2025-10-23 Dr. Reddy’S Laboratories Limited "amorphous solid dispersion of aficamten and process for their preparation"

Also Published As

Publication number Publication date
BR112022000523A2 (pt) 2022-03-03
MX2022000498A (es) 2022-02-03
US12649732B2 (en) 2026-06-09
EP3999181B1 (en) 2024-05-29
CN114667283B (zh) 2023-12-26
WO2021011809A1 (en) 2021-01-21
EP3999181C0 (en) 2024-05-29
AU2020315433A1 (en) 2022-03-03
NZ784931A (en) 2025-03-28
CN114667283A (zh) 2022-06-24
KR20220082803A (ko) 2022-06-17
US20220274969A1 (en) 2022-09-01
PH12022550084A1 (en) 2023-04-12
CA3144974A1 (en) 2021-01-21
TW202116764A (zh) 2021-05-01
IL289881A (en) 2022-03-01
JP2022542803A (ja) 2022-10-07
EP3999181A1 (en) 2022-05-25
ES2982707T3 (es) 2024-10-17

Similar Documents

Publication Publication Date Title
CL2022000054A1 (es) Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-car- boxamida.
JOP20250289A1 (ar) صور بلورية جديدة
NZ784931A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
MX388725B (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5.
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
IL260403B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PH12020500674A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
DK3908584T3 (da) Krystalformer af 1-(1,2-dimethylpropyl)-n-ethyl-5-methyl-n-pyridazin-4-ylpyrazol-4-carboxamid
UY38017A (es) Polimorfos de 4-[5-(3,5-dicloro-4-fluorofenil)-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-(2-etil-3-oxo-4-isoxazolidinil)-2-metilbenzamida
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
MX2022007660A (es) Tiofenocarboxamidas sustituidas y sus derivados.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX386696B (es) Proceso para producir analogos de anillo de arilomicina
MX381722B (es) Compuestos.
CO2021003295A2 (es) (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil)piperazin-1-carboxilato cristalino, composiciones y sus métodos de uso
HK40074727A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
EA201891102A1 (ru) Термодинамически стабильная кристаллическая модификация 2-метил-n-(5-метил-1,3,4-оксадиазол-2-ил)-3-(метилсульфонил)-4-(трифторметил)бензамида
PL436372A1 (pl) Nowe metabolity antazoliny do stosowania jako lek przeciwko migotaniu przedsionków
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.